Contemporary data on treatment practices for low-density lipoprotein cholesterol in 6794 patients with stable coronary heart disease across the world
Journal
Data in Brief
Journal Volume
18
Pages
1937-1940
Date Issued
2018
Author(s)
Anselm K. Gitt
Dominik Lautsch
Jean Ferrières
Gaetano M. De Ferrari
Ami Vyas
Carl A. Baxter
Lori D. Bash
Veronica Ashton
Martin Horack
Wael Almahmeed
Kian Keong Poh
Philippe Brudi
Baishali Ambegaonkar
Abstract
DYSIS II CHD was a longitudinal, observational study in 6794 patients from 18 countries. They were attending an outpatient physician appointment for coronary heart disease (CHD). 6370 patients (93.8%) were on active lipid lowering therapy (LLT). The mean atorvastatin dose equivalent was 25 mg per day and 10.5% received ezetimibe in combination with a statin. The mean low-density lipoprotein cholesterol (LDL-C) level was 88 mg/dL, with 29.4% of patients displaying a level below the 70 mg/dL target for very high-risk subjects.
Conclusion
While more than 90% of patients with CHD were on lipid lowering drugs, only three out of ten patients achieved their LDL-C target value.
Subjects
Low-density lipoprotein cholesterol
Treatment target
Global
Region
Statins
SDGs
Type
data paper